Cal­adrius’ 16-year rocky his­to­ry bends again in Cend merg­er; Af­ter Cel­lec­tis, Chi­na JV pacts, Cy­tovia inks SPAC deal

Af­ter a roller coast­er span­ning 16 years, Cal­adrius Bio­sciences thinks it can re­turn to sta­ble ground in a merg­er with lit­tle-known Cend Ther­a­peu­tics.

Cal­adrius will make an im­me­di­ate in­vest­ment of $10 mil­lion in­to the sol­id tu­mor-fo­cused San Diego biotech. Cend had al­ready at­tract­ed a part­ner for its lead on­col­o­gy as­set CEND-1 by sell­ing the Greater Chi­na rights to Qilu Phar­ma­ceu­ti­cal for $10 mil­lion up­front and $225 mil­lion in biobucks in Feb­ru­ary 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER